Combination Therapy with Famciclovir and Interferon-α for the Treatment of Chronic Hepatitis B
Interferon-α (IFN-α) treatment results in long-term remissions in only 25%–40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication. Five adults with chronic HBV infection in whom previous IFN-α therapy had failed were...
Saved in:
Published in | The Journal of infectious diseases Vol. 178; no. 5; pp. 1483 - 1487 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
The University of Chicago Press
01.11.1998
University of Chicago Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Interferon-α (IFN-α) treatment results in long-term remissions in only 25%–40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication. Five adults with chronic HBV infection in whom previous IFN-α therapy had failed were treated in a pilot study of overlapping IFNa and famciclovir therapy totaling 20 weeks. HBV DNA levels decreased by 0.9 log units during the initial 4-week period of famciclovir alone, followed by a further decrease of 1.8 logs during the middle 12-week period of combination therapy. HBV DNA rose by 0.9 log during the final 4-week period of IFN-α alone. Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. The combination of famciclovir and IFN-α appeared to be at least additive in suppressing HBV DNA. Efficacy trials of combination therapy with famciclovir and IFN-α are warranted. |
---|---|
AbstractList | Interferon-α (IFN-α) treatment results in long-term remissions in only 25%–40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication. Five adults with chronic HBV infection in whom previous IFN-α therapy had failed were treated in a pilot study of overlapping IFNa and famciclovir therapy totaling 20 weeks. HBV DNA levels decreased by 0.9 log units during the initial 4-week period of famciclovir alone, followed by a further decrease of 1.8 logs during the middle 12-week period of combination therapy. HBV DNA rose by 0.9 log during the final 4-week period of IFN-α alone. Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. The combination of famciclovir and IFN-α appeared to be at least additive in suppressing HBV DNA. Efficacy trials of combination therapy with famciclovir and IFN-α are warranted. Interferon-α (IFN-α) treatment results in long-term remissions in only 25%-40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication. Five adults with chronic HBV infection in whom previous IFN-aα therapy had failed were treated in a pilot study of overlapping IFNol and famciclovir therapy totaling 20 weeks. HBV DNA levels decreased by 0.9 log units during the initial 4-week period of famciclovir alone, followed by a further decrease of 1.8 logs during the middle 12-week period of combination therapy. HBV DNA rose by 0.9 log during the final 4-week period of IFN-a alone. Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. The combination of famciclovir and IFN-α appeared to be at least additive in suppressing HBV DNA. Efficacy trials of combination therapy with famciclovir and IFN-α are warranted. Interferon-alpha (IFN-alpha) treatment results in long-term remissions in only 25%-40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication. Five adults with chronic HBV infection in whom previous IFN-alpha therapy had failed were treated in a pilot study of overlapping IFN-alpha and famciclovir therapy totaling 20 weeks. HBV DNA levels decreased by 0.9 log units during the initial 4-week period of famciclovir alone, followed by a further decrease of 1.8 logs during the middle 12-week period of combination therapy. HBV DNA rose by 0.9 log during the final 4-week period of IFN-alpha alone. Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. The combination of famciclovir and IFN-alpha appeared to be at least additive in suppressing HBV DNA. Efficacy trials of combination therapy with famciclovir and IFN-alpha are warranted. |
Author | Marques, Adriana R. McKenzie, Robin Lau, Daryl T. Y. Hoofnagle, Jay H. Straus, Stephen E. |
Author_xml | – sequence: 1 givenname: Adriana R. surname: Marques fullname: Marques, Adriana R. email: amarques@atlas.niaid.nih.gov organization: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Liver Disease Section, Bethesda, Maryland – sequence: 2 givenname: Daryl T. Y. surname: Lau fullname: Lau, Daryl T. Y. organization: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Liver Disease Section, Bethesda, Maryland – sequence: 3 givenname: Robin surname: McKenzie fullname: McKenzie, Robin organization: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Liver Disease Section, Bethesda, Maryland – sequence: 4 givenname: Stephen E. surname: Straus fullname: Straus, Stephen E. organization: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Liver Disease Section, Bethesda, Maryland – sequence: 5 givenname: Jay H. surname: Hoofnagle fullname: Hoofnagle, Jay H. organization: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, and Liver Disease Section, Bethesda, Maryland |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1592708$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9780271$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkMFuEzEURS1UVNICf4DkBepuwB7P2OMlHbVNpUpsglplY9meZ8Vlxg62A_Sz-BG-iUGJktVbnKMjvXuBzkIMgNB7Sj5R0vHPjDYNI6_QgrZMVJxTdoYWhNR1RTsp36CLnJ8JIQ3j4hydS9GRWtAFUn2cjA-6-BjwagNJb1_wL182-FZP1tsx_vQJ6zDg-1AgOUgxVH__YBcTLhvAqwS6TBAKjg73m5l6i5ewnYPFZ3z9Fr12eszw7nAv0bfbm1W_rB6-3t33Xx4qy2RbKgmtZG6oh850lnZgYGDUNdwwyYxpNDeCUy3s4ByrCW3kIJhoLHWkNQYazS7R1b67TfHHDnJRk88WxlEHiLusuJRdTYU4iTbFnBM4tU1-0ulFUaL-L6n2S87ih0NxZyYYjtphupl_PHCdrR5d0sH6fKq1shakO2Wec4npiBmhdH6Bz7zac58L_D5ynb4rPgutWj6t1Xrd3z3StlXX7B9GH5WG |
CODEN | JIDIAQ |
CitedBy_id | crossref_primary_10_1046_j_1440_1746_17_s4_9_x crossref_primary_10_1016_S1089_3261_05_70096_9 crossref_primary_10_1097_00001432_199910000_00011 crossref_primary_10_1016_S0025_7753_00_71539_9 crossref_primary_10_1111_jvh_12341 crossref_primary_10_1007_BF03040276 crossref_primary_10_1046_j_1365_2893_2001_00303_x crossref_primary_10_1034_j_1399_3062_2001_003001016_x crossref_primary_10_1016_S0166_3542_01_00179_6 crossref_primary_10_1586_17474124_2016_1145547 crossref_primary_10_1258_0956462011923930 crossref_primary_10_1007_s11938_999_0050_1 crossref_primary_10_3748_wjg_v9_i7_1491 crossref_primary_10_1177_135965350000500406 crossref_primary_10_1007_s11894_002_0039_6 crossref_primary_10_1007_s11901_003_0022_1 crossref_primary_10_1016_S1386_6532_02_00189_0 crossref_primary_10_1002_rmv_393 crossref_primary_10_1002_hep_510300238 crossref_primary_10_1159_000024972 crossref_primary_10_1053_jhep_2000_16181 crossref_primary_10_1111_j_1478_3231_2004_0889_x crossref_primary_10_2165_00003495_200060030_00001 crossref_primary_10_1021_np050239z crossref_primary_10_1179_joc_2002_14_3_285 |
ContentType | Journal Article |
Copyright | Copyright 1980 The University of Chicago 1999 INIST-CNRS |
Copyright_xml | – notice: Copyright 1980 The University of Chicago – notice: 1999 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1086/314430 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 1487 |
ExternalDocumentID | 10_1086_314430 9780271 1592708 30117376 ark_67375_HXZ_ZZCGW155_B |
Genre | Clinical Trial Research Support, U.S. Gov't, P.H.S Journal Article |
GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 3O- 4.4 41~ 48X 53G 5GY 5RE 5VS 5WD 6.Y 70D 85S AABJS AABMN AABZA AACGO AACZT AAESY AAHTB AAIYJ AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AASNB AAUQX AAVAP AAWDT AAWTL AAYOK ABBHK ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPTD ABQLI ABSAR ABSMQ ABTLG ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACGOD ACIMA ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ADACV ADBBV ADEIU ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADULT ADVEK ADYVW ADZLD ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFHKK AFIYH AFOFC AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AIKOY AIMBJ AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS AQVPL AQVQM ASMCH AVNTJ AWCFO AXUDD AZQFJ BAWUL BAYMD BCRHZ BEYMZ BGYMP BHONS BR6 BSCLL BTRTY BVRKM BYORX BZKNY C45 CASEJ CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DNJUQ DOOOF DPORF DPPUQ DU5 DWIUU D~K EBS ECGQY EE~ EIHJH EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK G8K GAUVT GJXCC GX1 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MBLQV MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P0- P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W2D W8F WH7 X7H X7M Y6R YAYTL YKOAZ YXANX ZA5 ZE2 ZGI ZKG ZXP ~91 AANRK AHPSJ ALXQX 08R AAUGY ABPTK H13 IQODW OBFPC AAHBH AAUAY ABQNK ACZBC ADQBN AFSHK AGMDO ATGXG CGR CUY CVF ECM EIF IPSME NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c395t-9e593fd2d8b8c18ebed31f46b393bb4a6b761a7cdff320149d7374c1f05bbe4a3 |
ISSN | 0022-1899 |
IngestDate | Fri Aug 16 21:44:29 EDT 2024 Fri Aug 23 02:00:59 EDT 2024 Wed Oct 16 00:51:46 EDT 2024 Sun Oct 29 17:11:01 EDT 2023 Fri Feb 02 08:15:49 EST 2024 Sun Mar 31 11:39:34 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Purine nucleoside Alpha interferon Cytokine Orthohepadnavirus Hepatic disease Famciclovir Infection Virus Viral hepatitis B Chemotherapy Hepadnaviridae Immunotherapy Viral disease Digestive diseases Antiviral Combined treatment Hepatitis B virus |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c395t-9e593fd2d8b8c18ebed31f46b393bb4a6b761a7cdff320149d7374c1f05bbe4a3 |
Notes | Presented in part: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 28 September to 1 October 1997 (paper H-035). ark:/67375/HXZ-ZZCGW155-B istex:129D507C3C08C1C3BBBD0C87C323803A3EC82B75 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://academic.oup.com/jid/article-pdf/178/5/1483/2426726/178-5-1483.pdf |
PMID | 9780271 |
PQID | 69982177 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_69982177 crossref_primary_10_1086_314430 pubmed_primary_9780271 pascalfrancis_primary_1592708 jstor_primary_30117376 istex_primary_ark_67375_HXZ_ZZCGW155_B |
PublicationCentury | 1900 |
PublicationDate | 1998-11-01 |
PublicationDateYYYYMMDD | 1998-11-01 |
PublicationDate_xml | – month: 11 year: 1998 text: 1998-11-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Chicago, IL |
PublicationPlace_xml | – name: Chicago, IL – name: United States |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAlternate | The Journal of Infectious Diseases |
PublicationYear | 1998 |
Publisher | The University of Chicago Press University of Chicago Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
SSID | ssj0004367 |
Score | 1.752415 |
Snippet | Interferon-α (IFN-α) treatment results in long-term remissions in only 25%–40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the... Interferon-α (IFN-α) treatment results in long-term remissions in only 25%-40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir, the... Interferon-alpha (IFN-alpha) treatment results in long-term remissions in only 25%-40% of patients with chronic hepatitis B virus (HBV) infection. Famciclovir,... |
SourceID | proquest crossref pubmed pascalfrancis jstor istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1483 |
SubjectTerms | 2-Aminopurine - analogs & derivatives 2-Aminopurine - therapeutic use Adult Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Aspartate Aminotransferases - blood Biological and medical sciences Biopsies Chronic hepatitis DNA DNA, Viral - analysis Drug Therapy, Combination Famciclovir Fibrosis Hepatitis antigens Hepatitis B virus Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Histology Human viral diseases Humans Infections Infectious diseases Interferon-alpha - therapeutic use Liver Liver diseases Male Medical sciences Pharmacology. Drug treatments Viral diseases Viral hepatitis |
Title | Combination Therapy with Famciclovir and Interferon-α for the Treatment of Chronic Hepatitis B |
URI | https://api.istex.fr/ark:/67375/HXZ-ZZCGW155-B/fulltext.pdf https://www.jstor.org/stable/30117376 https://www.ncbi.nlm.nih.gov/pubmed/9780271 https://search.proquest.com/docview/69982177 |
Volume | 178 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagVVEvCApVF1rwAXELSuI4do60Kl1VLBdasdpLZDuxVFCzVTZb0f56xo84adVKwCWK4keifN9MxvE8EPpQmHpITOooKWQcZXUVR4KKOKKF5lTkIqtsSqHZt3x6np3O6XwIIbDRJZ38pG4fjCv5H1ThGuBqomT_AdkwKVyAc8AXjoAwHP8KYxBmWNg6CF0g1Y37sarFpYLOy-uL1qdXMtWo63bZRDa4NjgXDn7mxr3cJcoF49G4WXcXK1-S-efAqNNxognnxrVe9bs8wTyfidZ8bpzeCVtJX8XaarjBL3umQM_fuh2S0M3ky13bsd99mEQVovSS8FNiCBJIuKt9FBQt4yNG0ZHahDUZeVCfx3Z7icCqz-3ejEC9urSomgxKqavici9xtm95ijZTVlDj7nkyH9x_MpKzPpO8edBR3Sl3u2205We4Y7JsGun73XuvGldasQJp0q4MyuPrFGuvnL1Azz1Q-LNjzUv0pG520JYrPXqzg57NvFPFKyRHNMKeRtjQCI9ohIFG-D6NMNDIjMCBRnipsacRDjTCh6_R-Zfjs6Np5EtvRIoUtIuKmhZEV2nFJVcJB0mvSKKzXJKCSJmJXLI8EUxVWpPUrLIrkPhMJTqmUtaZILtoo1k29R7CMWdwHWaRRGecpqJSitYcLG0lqY75BL3v32555TKslNYzguelQ2KCPtqXHppF-8v4IzJaTueLcrE4OvkBZnF5OEG7FpXQ0Xy9oF8-QQd3YBpuRIuU2WfoYStBvZo9M9HUIEBlDuSGVTuDqR2aYagnx5vHGt6i7UEy9tFG167rAzBgO_nOMvEPU_easg |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+therapy+with+famciclovir+and+interferon-alpha+for+the+treatment+of+chronic+hepatitis+B&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Marques%2C+A+R&rft.au=Lau%2C+D+T&rft.au=McKenzie%2C+R&rft.au=Straus%2C+S+E&rft.date=1998-11-01&rft.issn=0022-1899&rft.volume=178&rft.issue=5&rft.spage=1483&rft_id=info:doi/10.1086%2F314430&rft_id=info%3Apmid%2F9780271&rft.externalDocID=9780271 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |